New meta-analysis finds cannabis may be linked to development of opioid use disorders

 

Northampton, UK (July 15, 2021) — The idea that cannabis is a ‚gateway drug‘ to more harmful substances such as opioids is controversial, yet has substantially impacted drug policy, education and how we conceptualize substance use. A new systematic review and meta-analysis has found that people who use cannabis are disproportionately more likely to initiate opioid use and engage in problematic patterns of use than people who do not use cannabis. But the quality of the evidence for this finding is low.

One surprising discovery in this meta-analysis, led by researchers at the University of Sydney’s Matilda Centre for Research in Mental Health and Substance Use and published by the journal Addiction, was that there aren’t many good studies on the gateway drug theory. Despite the frequency with which the topic of gateway drugs is discussed, only six studies were of high enough quality to include. A synthesis of the evidence from those six studies demonstrated that people who use cannabis are more than twice as likely to initiate opioid use and develop problematic patterns of use than people who don’t use cannabis.

But the quality of the evidence in those studies is low and must be interpreted with caution. All six studies had a moderate risk of bias and overlooked important confounding variables such as cannabis use frequency and affiliation with cannabis or opioid-using peers. It is unclear whether these unmeasured variables would have had a strong enough impact to explain away the cannabis-opioid use relationship.

It is therefore not possible, on the existing evidence, to state conclusively that there is a causal relationship between cannabis and subsequent opioid use, but it is likely that there is at least a partial causal relationship.

The six studies provided data from the United States, Australia and New Zealand between 1977 and 2017, with a total sample of 102,461 participants.

 

 

 

For editors:

Peer reviewed: Yes
Type of study: Review
Subject of study: People
Funding: Government/research council, charity/NGO, and university

This paper is free to download for one month from the Wiley Online Library: https://onlinelibrary.wiley.com/doi/abs/10.1111/add.15581 or by contacting Jean O’Reilly, Editorial Manager, Addiction, jean@addictionjournal.org.

A podcast with Mr Jack Wilson is available at Addiction Audio: https://shows.acast.com/addiction-audio

Full citation for article: Wilson J, Mills K, Freeman TP, Sunderland M, Visontay R, and Marel C. (2021) Weeding out the truth: a systematic review and meta-analysis on the transition from cannabis use to opioid use and opioid use disorders, abuse or dependence. Addiction 116: doi:10.1111/add.15581

Funding: Project supported by the Australian National Health and Medical Research Council (NHMRC), the University of Sydney’s Matilda Centre for Research in Mental Health and Substance Use, the University of Sydney, and the Society for the Study of Addiction.

 

Addiction (http://www.addictionjournal.org) is a monthly international scientific journal publishing peer-reviewed research reports on alcohol, substances, tobacco, and gambling as well as editorials and other debate pieces. Owned by the Society for the Study of Addiction, it has been in continuous publication since 1884.

 

 


Society for the Study of Addiction, 15.07.2021 (tB).

Schlagwörter: , ,

MEDICAL NEWS

IU School of Medicine researchers develop blood test for anxiety
COVID-19 pandemic increased rates and severity of depression, whether people…
COVID-19: Bacterial co-infection is a major risk factor for death,…
Regenstrief-led study shows enhanced spiritual care improves well-being of ICU…
Hidden bacteria presents a substantial risk of antimicrobial resistance in…

SCHMERZ PAINCARE

Hydromorphon Aristo® long ist das führende Präferenzpräparat bei Tumorschmerz
Sorgen und Versorgen – Schmerzmedizin konkret: „Sorge als identitätsstiftendes Element…
Problem Schmerzmittelkonsum
Post-Covid und Muskelschmerz
Kopfschmerz bei Übergebrauch von Schmerz- oder Migränemitteln

DIABETES

Wie das Dexom G7 abstrakte Zahlen mit Farben greifbar macht…
Diabetes mellitus: eine der großen Volkskrankheiten im Blickpunkt der Schmerzmedizin
Suliqua®: Einfacher hin zu einer guten glykämischen Kontrolle
Menschen mit Diabetes während der Corona-Pandemie unterversorgt? Studie zeigt auffällige…
Suliqua® zur Therapieoptimierung bei unzureichender BOT

ERNÄHRUNG

Positiver Effekt der grünen Mittelmeerdiät auf die Aorta
Natriumaufnahme und Herz-Kreislaufrisiko
Tierwohl-Fleisch aus Deutschland nur mäßig attraktiv in anderen Ländern
Diät: Gehirn verstärkt Signal an Hungersynapsen
Süßigkeiten verändern unser Gehirn

ONKOLOGIE

Strahlentherapie ist oft ebenso effizient wie die OP: Neues vom…
Zanubrutinib bei chronischer lymphatischer Leukämie: Zusatznutzen für bestimmte Betroffene
Eileiter-Entfernung als Vorbeugung gegen Eierstockkrebs akzeptiert
Antibiotika als Störfaktor bei CAR-T-Zell-Therapie
Bauchspeicheldrüsenkrebs: Spezielle Diät kann Erfolg der Chemotherapie beeinflussen

MULTIPLE SKLEROSE

Multiple Sklerose: Aktuelle Immunmodulatoren im Vergleich
Neuer Biomarker für Verlauf von Multipler Sklerose
Multiple Sklerose: Analysen aus Münster erhärten Verdacht gegen das Epstein-Barr-Virus
Aktuelle Daten zu Novartis Ofatumumab und Siponimod bestätigen Vorteil des…
Multiple Sklerose durch das Epstein-Barr-Virus – kommt die MS-Impfung?

PARKINSON

Meilenstein in der Parkinson-Forschung: Neuer Alpha-Synuclein-Test entdeckt die Nervenerkrankung vor…
Neue Erkenntnisse für die Parkinson-Therapie
Cochrane Review: Bewegung hilft, die Schwere von Bewegungssymptomen bei Parkinson…
Technische Innovationen für eine maßgeschneiderte Parkinson-Diagnostik und Therapie
Biomarker und Gene: neue Chancen und Herausforderungen für die Parkinson-Diagnose…